Source link : https://www.newshealth.biz/health-news/truqap-combo-earns-eu-approval-for-advanced-breast-cancer/
Truqap (capivasertib, AstraZeneca) in combination with Faslodex (fulvestrant) has been approved by the European Commission for the treatment of adult patients with: estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN alterations; and who have experienced recurrence or progression on […]
Author : News Health
Publish date : 2024-06-21 14:45:46
Copyright for syndicated content belongs to the linked Source.
Categories